|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | C07D 231/38 | (2006.01) |
| C07D 405/10 | (2006.01) | ||
| C07D 233/88 | (2006.01) | ||
| C07D 401/06 | (2006.01) | ||
| A61K 31/415 | (2006.01) | ||
| A61P 29/00 | (2006.01) |
| (11) | Number of the document | 2298743 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10164367.4 |
| Date of filing the European patent application | 2004-06-24 | |
| (97) | Date of publication of the European application | 2011-03-23 |
| (45) | Date of publication and mention of the grant of the patent | 2012-08-22 |
| (46) | Date of publication of the claims translation | 2012-12-27 |
| (30) | Number | Date | Country code |
| 483428 P | 2003-06-26 | US | |
| 499054 P | 2003-08-29 | US | |
| 560481 P | 2004-04-07 | US |
| (72) |
Fryszman, Olga M., US
Lang, Hengyuan, US
Lan, Jiong, US
Chang, Edcon, US
Fang, Yunfeng, US
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | P38 kinazės inhibitoriai penkianarių heterociklų pagrindu |
| 5-membered heterocycle-based P38 kinase inhibitors |
| Payment date | Validity (years) | Amount | |
| 2022-06-20 | 19 | 347.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2023-06-24 |